TY  - GEN
AU  - Amorim,Sandy
AU  - Stathis,Anastasios
AU  - Gleeson,Mary
AU  - Iyengar,Sunil
AU  - Magarotto,Valeria
AU  - Leleu,Xavier
AU  - Morschhauser,Franck
AU  - Karlin,Lionel
AU  - Broussais,Florence
AU  - Rezai,Keyvan
AU  - Herait,Patrice
AU  - Kahatt,Carmen
AU  - Lokiec,François
AU  - Salles,Gilles
AU  - Facon,Thierry
AU  - Palumbo,Antonio
AU  - Cunningham,David
AU  - Zucca,Emanuele
AU  - Thieblemont,Catherine
TI  - Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
SN  - 2352-3026
PY  - 2017///1018
KW  - Acetanilides
KW  - administration & dosage
KW  - Aged
KW  - Antineoplastic Agents
KW  - Drug Administration Schedule
KW  - Female
KW  - France
KW  - Heterocyclic Compounds, 3-Ring
KW  - Humans
KW  - Italy
KW  - Lymphoma
KW  - drug therapy
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Switzerland
KW  - United Kingdom
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2352-3026(16)00021-1
ER  -